

Is Alzheimer's in my Genes?

Separating Fact from Fiction

July 13, 2017

 Alzheimer's | SAN DIEGO

UC San Diego

 Scripps

Alzheimer's | SAN DIEGO

The Heart of Alzheimer's Care & Cure

Our Mission: to provide San Diego families with care and support,
while advancing critical local research for a cure.

100%
OF DOLLARS
RAISED STAY
IN **SAN DIEGO**

Local & Independent

Alzheimer's San Diego is NOT
affiliated with a national
organization or association.

 Alzheimer's | SAN DIEGO

UC San Diego

 Scripps

Alzheimer's | SAN DIEGO

The Heart of Local Care & Cure



Free in-person support from local experts

Alzheimer's | SAN DIEGO

UC San Diego

Scripps

Meet the Experts



Dr. Michael Lobatz
Medical Director,
Scripps Health
Neurosciences



Dr. William Mobley
Associate Dean,
UCSD Dept. of
Neurosciences



Dr. Terry Gaasterland
Director, Scripps
Genome Center



Dr. Lisa Madlensky
Genetic Counselor &
Professor, UCSD


Alzheimer's | SAN DIEGO

UC San Diego

Scripps

Introduction to Genetics of Alzheimer's Disease

Dr. Michael Lobatz
Medical Director, Scripps Health Neurosciences



"Age carries all things away, even the mind"

Virgil 70 B.C. – 17 B.C.

 Alzheimer's | SAN DIEGO

UC San Diego

 Scripps

A Local Epidemic

65K

LIVING WITH
ALZHEIMER'S
IN SAN DIEGO

#3

CAUSE OF
DEATH IN
SAN DIEGO

+200K

SAN DIEGANS
CARING FOR A
LOVED ONE

 Alzheimer's | SAN DIEGO

UC San Diego

 Scripps

The most expensive disease in America

National cost of caring for people with Alzheimer's and other dementias

\$226 billion in 2015

that number is set to reach

\$1.1 trillion in 2050



Terminology

Dementia

- An acquired syndrome consisting of a decline in memory and other cognitive functions
- Dementia is a word for a group of symptoms caused by disorders that affect the brain. It is not a specific disease.

Types of Dementia




- Alzheimer's disease is the most common type of dementia
- Lewy body disease is one of the leading causes of dementia in elderly adults
- Many small strokes - vascular dementia

RECOMMENDED SCREENING ALGORITHM FOR ADULT COGNITIVE IMPAIRMENT


NOTE: Cognitive screening may be a part of a regular annual physical exam.

10 WARNING SIGNS

- 1 Memory loss disrupts daily life
- 2 Challenges in planning or problem solving
- 3 Difficulty completing familiar tasks
- 4 Confusion with time or place
- 5 Trouble understanding visual images or spatial relationships
- 6 Problems with words
- 7 Misplacing items and inability to retrace steps
- 8 Decreased or poor judgment
- 9 Withdrawal from work or social activities
- 10 Changes in mood and personality




Symptomatic Progression



MMSE = Mini-Mental State Examination

Adapted with permission from Feldman et al. *Clinical Diagnosis and Management of Alzheimer's Disease*. 1999:249-268.

Progressive Loss of Activities of Daily Living



Adapted from Galasko D, et al. *Eur J Neurol*. 1998;5(suppl 4):S9-S17.

Alzheimer's | SAN DIEGO

UC San Diego

Scripps

Getting a Diagnosis


- A physician should be consulted
- For people with dementia and their families, an early diagnosis has many advantages:
 - time to make choices that maximize quality of life
 - lessened anxieties about unknown problems
 - a better chance of benefiting from treatment
 - more time to plan for the future



Alzheimer's | SAN DIEGO

UC San Diego

Scripps



Current FDA Approved Treatments

Not Disease Modifying

Agent	Donepezil (Aricept)	Rivastigmine (Exelon)	Galantamine (Razadyne)	Memantine (Namenda)
Dose Range	5-23mg/d	3-12mg/d	8-24mg/d	5-20mg/d
Target Dose	5-10mg/d	6-12mg/d or Patch	16-24mg/d	10-20mg/d
Most Common Adverse Events (Drug-Placebo)	Nausea (13%) Diarrhea (10%) Insomnia (8%)	Nausea (35%) Vomiting (25%) Dizziness (10%)	Nausea (12%) Vomiting (9%) Anorexia (6%)	Headaches(3%) Dizziness (2%) Constipation(2%)


Alzheimer's | SAN DIEGO UC San Diego Scripps

Manage the Patient and Caregiver

- Schedule follow-up visits (at least every 6 months)
- Repeat assessment of cognition, function, and behavior
- Monitor patient safety and caregiver burden
- Refer to specialists when necessary
 - eg, refractory behavioral disturbances, emergent neurologic symptoms

Support Caregivers and Families

- Provide information on the disease process
- Introduce respite care early and describe full range of benefits available
- Identify members of a healthcare team (physician, nurse, social worker, psychologist) and support services
 - Refer caregivers for planning for future financial and legal issues
- Contact **Alzheimer's San Diego**



Alzheimer's Disease: Biology of Memory Loss

William C Mobley M.D., Ph.D.
Department of Neurosciences
University of California, San Diego

 Alzheimer's | SAN DIEGO

 UC San Diego

 Scripps

Exploring the Causes of Alzheimer's


- Reduced brain size – atrophy
- Changes in microscopic structure – synaptic and neuronal loss with reduced brain metabolic activity
- Neuropathological markers – plaques, tangles, etc
- Disruption of cellular and molecular structure and function
- Genetic risk factors

 Alzheimer's | SAN DIEGO


 UC San Diego

 Scripps


Information Flow in Brain: Supports Neuron Function




Information Flow in Brain: Critical Role for the Synapse




Information Flow in Brain: Synapse Under Attack



Information Flow in Brain: Supports Neuron Function




Noticeable Brain Atrophy



Brain Pathology in Alzheimer's disease

Cortex



Biomarkers to Aid in Diagnosis and Treatment




Structure:

MRI whole brain atrophy
regional atrophy
connectivity - DTI

Function:


fMRI ↓ activation/ default network
PET, SPECT ↓ glucose use



Biochemistry:

CSF $A\beta_{42}$ ↓
tau, P-tau ↑
PET amyloid deposition
tau deposition
Plasma $A\beta$


Volumetric MRI



NORMAL

ALZHEIMER'S DISEASE

FDG PET Scans are Abnormal in AD




Alzheimer's | SAN DIEGO

UC San Diego

Scripps

PET Imaging to Detect Amyloid



Amyloid imaging detects fibrillar deposits of $\text{A}\beta$ in plaques.

These arise years before people develop memory loss


About 30% of people aged 70 have positive scans

Alzheimer's | SAN DIEGO

UC San Diego


Scripps

Tau PET Imaging



Rafii et al.,
J Alz Dis,
In press.

Current Diagnosis and Treatment May Come Too Late



Decoding a genome

sagtggdaagtgktdoqhmseagtgnqsagtggdbagtgdkkhagtgrhagtgmsagtggdcagtgmb

agtg → “ “

“s gda ktdoqhmse nqs gdc dkkh rh ms gdc mb”

Add 1 to every letter: a → b ... s → t...

“t heb lueprintf ort hec elli si nt hed na”

Shift “ ” left

“the blueprint for the cell is in the dna”

Single Nucleotide Polymorphism (SNP) truisms

- One base difference amongst individuals
(e.g., **A** instead of **G**)
- About **one per 1000** base pairs in human genome
- **~3 million “common” SNPs** in human genome
- Many, many more **“rare”** SNPs
- Each SNP's **frequency** is stable in a population
- Many SNPs **occur in or near genes**

Decoding a genome with SNPs

sagtggdaagtgktdoqhmseagtgnqsagtggdcagtgdkkhagtgrhagtgmsagtggdcagtgmb
sagtggdaagtgktdoqhmseagtgnqsagtggdbagtgdkkhagtgrhagtgmsagtggdcagtgmb

agtg → “ “

“s gda ktdoqhmse nqs gdb dkkh rh ms gdc**cg**tgmb”

Add 1 to every letter: a → b ... s → t...

“t heb lueprintf ort heb**b** elli si nt hed**dh**uhna”

Shift “ ” left

“the blueprint for the **b**ell is in the**ed**dhuhna”

“Complex” genetics = many genes + environment

- Childhood diseases tend to be “**monogenic**”

One gene, **one copy** : **dominant**

One gene, **both copies** : **recessive**

- Later onset diseases tend to be “**complex**”

Multiple genes

+ **Environment**

+ **Somatic mutations** + ...


Insights from Island Populations

Genome-Wide Association Studies in an Isolated Founder Population from the Pacific Island of Kosrae

Jennifer K. Lowe, Julian B. Maller, Itsik Pe'er, Benjamin M. Neale, Jacqueline Saitt, Eimear E. Kenny, Jessica L. Shea, Ralph Burkhardt, J. Gustav Smith, Weizhen Ji, Martha Noel, Jia Nee Foo, Mau



[view all]

Published: February 6, 2009 • <https://doi.org/10.1371/journal.pgen.1000365>



- Genes for diabetes, obesity, hypertension
- Required an environmental change
- Western diet (e.g., potato chips...!)

Insights from Island Populations



- Genes for diabetes, obesity, hypertension
- Required an environmental change
- Western diet (e.g., potato chips...!)

Clues to genetics from twins


If **one SNP** leads to disease/trait:

Identical twins:
Concordance = **100%**
AND

Fraternal twins:
Concordance = **50%**

Discordant = one twin

Concordant = both twins



Clues to genetics from twins


If **several genes** lead to disease/trait:

Identical twins:
Concordance **HIGHER**
AND

Fraternal twins:
Concordance **LOWER**

Discordant = one twin

Concordant = both twins




Clues to genetics from twins

If environment contributes to disease/trait:


Difference between Identical twins AND Fraternal twins shrinks

Discordant = one twin

Concordant = both twins



Alzheimers Disease in Twins



- 392 twin pairs, one or both with AD
(drawn from Swedish Twin Registry, 11 884 pairs)
- Estimated heritability: **58%**
- Gender independent
- Genetic influence on age of onset

Role of Genes and Environments for Explaining Alzheimer Disease
Gatz et al, 2006, Arch. Gen. Psych.

Population truisms

- Any one population includes ~90% of genetic variation found worldwide
- Common SNPs - in all human populations
- Thus, a map of SNPs can be developed with samples from any one population


BUT! SNP frequencies differ.

Insights from Many Genomes


Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

The Wellcome Trust Case Control Consortium*

There is increasing evidence that genome-wide association (GWA) studies represent a powerful approach to the identification of genes involved in common human diseases. We describe a joint GWA study (using the Affymetrix GeneChip 500K Mapping Array Set) undertaken in the British population, which has examined ~2,000 individuals for each of 7 major diseases and a shared set of ~3,000 controls. Case-control comparisons identified 24 independent association signals at $P < 5 \times 10^{-7}$; 1 in bipolar disorder, 1 in coronary artery disease, 9 in Crohn's disease, 3 in rheumatoid arthritis, 7 in type 1 diabetes and 3 in type 2 diabetes. On the basis of prior findings and replication studies thus far completed, almost all of these signals reflect genuine susceptibility effects. We observed association at many previously identified loci, and found compelling evidence that some loci confer risk for more than one of the diseases studied. Across all diseases, we identified a large number of further signals (including 58 loci with single-point P values between 10^{-9} and 5×10^{-7}) likely to yield additional susceptibility loci. The importance of appropriately large samples was confirmed by the modest effect sizes observed at most loci identified. This study thus represents a thorough validation of the GWA approach. It has also demonstrated that careful use of a shared control group represents a safe and effective approach to GWA analyses of multiple disease phenotypes; has generated a genome-wide genotype database for future studies of common diseases in the British population; and shown that, provided individuals with non-European ancestry are excluded, the extent of population stratification in the British population is generally modest. Our findings offer new avenues for exploring the pathophysiology of these important disorders. We anticipate that our data, results and software, which will be widely available to other investigators, will provide a powerful resource for human genetics research.



Genetic Risk in Alzheimers



- **Early onset:**
3+ genes,
hardly explained

Cacace et al, 2016, Alzheimers Dement.

- **Later onset:**
20+ genes by GWAS
28% of heritability

Van Cauwenberghe et al, 2016, Genetic Med.

APOE algebra

- Everyone has 2 copies of APOE
- APOE**E4** **14%** (*European population copies*)
- APOE**E4,4** = 14%*14% = **2%** **higher risk**
- APOE**E2** **7%**
- APOE**E2,2** = **0.5%** **later onset**
- APOE**E2,4** = **1%** **mixed**

What does “higher risk” mean?

Alzheimer’s Disease Sequencing Project


>10,000 genomes

▲ no AD n = 4,107

autopsied cases, Braak 4+

● E4- n = 1,585

● E4+ n = 1,007



<https://www.niagads.org/adsp>

Genetic Counseling and Testing

Lisa Madlensky, PhD, CGC
Program Director & Genetic Counselor
Family Cancer Genetics Program
Moore's UCSD Cancer Center

Professor
Division of Medical Genetics, Dept. of Medicine
University of California San Diego



 Alzheimer's | SAN DIEGO

UC San Diego

 Scripps

Genetic Counseling and Testing

- We are here to help!
- May be challenging to find a clinic; now online/telephone genetic counseling is widely available
- Identify goals, talk through pros and cons.
- Is this really “testing”? Or one component of a risk assessment?
- You can always consider testing in the future... but once you have tested you can't go back

 Alzheimer's | SAN DIEGO

UC San Diego

 Scripps

Genetic test results

- Once you look, you can't "unsee" the results
- Are you able to set the information aside? Or will you worry more?
- Everyone hopes to see no increase in risk...
 - But what if you do have an increased risk?
 - What if results aren't what you expected?
 - What if family members do this together?



Direct-to-consumer testing

I recently sent my personal raw data file, from 23andMe, to Promethease.com, for health-related information based on my genome.

In my Promethease report, I received some alarming information related to my risk of developing Alzheimer's Disease (AD). I appear to have two copies of the APOE e4 gene, which gives me an 11x greater-than-average chance of developing Late Onset AD.

There was other unsettling and also confusing information in my report.

I'm interested in meeting with a genetic counselor to 1) receive instruction on how to read and understand my Promethease report and 2) better understand the implications of my homozygous APOE e4 status, as well as the other health risks flagged.

-email to me from a patient

Things to consider

- What is the goal of testing?
- What would you do differently if increased risk? If decreased risk?
- Individuals with anxiety, depression, *prior to testing* are more likely to experience increased anxiety, depression
- *"I just wanted to do ancestry testing; I didn't know I could look at my APOE results"*

Results from the REVEAL study (2009)

Conclusions

The disclosure of *APOE* genotyping results to adult children of patients with Alzheimer's disease did not result in significant short-term psychological risks. Test-related distress was reduced among those who learned that they were *APOE* $\epsilon 4$ -negative. **Persons with high levels of emotional distress before undergoing genetic testing were more likely to have emotional difficulties after disclosure.**

Green et al, N Engl J Med 2009; 361:245-254

Results from the REVEAL study (2009)

Methods

Study Population and Instruments

We recruited adult children of a living or deceased parent with Alzheimer's disease through self-referral or telephone calls to families in research registries. As part of the screening process, we interviewed the subjects and administered standardized tests to evaluate their cognitive ability, academic achievement, and levels of anxiety and depression. We excluded subjects who scored 1.3 SD below norms on the Repeatable Battery for the Assessment of Neuropsychological Status or the Wide Range Achievement Test 3; higher than 20 on the Beck Anxiety Inventory (BAI), which ranges from 0 to 63, with higher scores indicating greater anxiety; or higher than 26 on the Center for Epidemiological Studies Depression Scale (CES-D), which ranges from 0 to 60, with higher scores indicating greater depression

Green et al, N Engl J Med 2009; 361:245-254

Summary

- Know yourself- do a thought experiment
- Have genetic counseling at the ready
- It may be difficult to obtain pre-test genetic counseling in San Diego; easier to obtain post-test
- APOE status is a risk/protective factor. Not a diagnosis.



Questions?